喹诺酮类一临床应用1、泌尿生殖系统感染2、呼吸系统感染：可用于对青霉素高度耐药的肺炎链球菌感染可替代大环内酯类用于支原体、衣原体肺炎，嗜肺军团菌引起的军团病。环丙沙星、左氧氟沙星可有效治疗结核。3、肠道感染：用于多种细菌引起的腹泻、胃肠炎和细菌性痢疾伤寒与副伤寒。4、骨骼系统感染5、皮肤软组织感染6、其他
喹诺酮类—临床应用 1、泌尿生殖系统感染 2、呼吸系统感染：可用于对青霉素高度耐药的肺炎链球菌感染， 可替代大环内酯类用于支原体、衣原体肺炎，嗜肺军团菌引起的军 团病。环丙沙星、左氧氟沙星可有效治疗结核。 3、肠道感染：用于多种细菌引起的腹泻、胃肠炎和细菌性痢疾， 伤寒与副伤寒。 4、骨骼系统感染 5、皮肤软组织感染 6、其他
喹诺酮类一临床不推荐应用的情况Restrictionsontheuseof fluoroquinoloneantibioticswillmeanthattheyshouldnotbeDisablingandpotentiallypermanentside金used:effectsleadtosuspensionorrestrictionstotreatinfectionsthatmightgetbetterwithouttreatmentorarenotsevere(suchasofquinoloneandfluoroquinolonethroat infections);:antibioticsto treatnon-bacterial infections,e.g.non-bacterial (chronic)prostatitis;(Ret:EMA)November16th,2018forpreventingtraveller'sdiarrhoea orrecurring lowerurinarytract infections(urineTags: Press Release cinoxacin flumeguine nalidixic acid Riremidicacld Furonean Unioninfections that do not extend beyond the bladder);EMA Bacteriel Infeclions Infectious Diseases IntemalMedicine Regulatory Affaitstotreatmildormoderatebacterial infectionsunlessotherantibacterialmedicinesEMAhasreviewedserious,disablingandpotentiallypermanentcommonly recommended for these infections cannot be used.sideeffectswithquinoloneand fluoroquinoloneantibioticsgivenbyin Sharemouth.iniectionorinhalation.Thereviewincorporatedtheviewsopatients,healthcareprofessionals.andacademicspresentedatTweetEMA's public hearing on fluoroquinolone and quinolone antibioticsInJune2018.@EmalloPrintEMA'shumanmedicinescommittee(CHMP)hasendorsedtherecommendationsof EMA'ssafetycommittee(PRAC)andconcludedthatthemarketingauthorisationofmedicinescontainingcinoxacin,flumequine,nalidixicacid,andpipemidicacidshouldbesuspended
喹诺酮类—临床不推荐应用的情况
喹诺酮类一不良反应1、胃肠道反应：与剂量有关2、中枢神经系统反应：可以透过BBB，机制与药物阻断中枢GABA受体有关。轻症表现为失眠、头疼，重症出现幻觉、抽搐甚至惊厥。常在剂量过大，或有精神病、癫痫史，与茶碱、非留体抗炎药合用时产生。3、皮肤反应和光敏反应：少数患者发生光敏反应，表现为光照部位红肿、痒和灼热感，严重可出现皮肤糜烂和脱落。光敏反应与喹诺酮类药物结构有关，其中司帕沙星、洛美沙星、氟罗沙星最易导致光敏反应。4、软骨损害：软骨组织中的镁离子易与药物形成络合物，沉积于关节软骨，造成局部Mg2+缺乏致软骨损伤。孕妇和18岁以下禁用。5、其他：环丙沙星、氧氟沙星、吉米沙星、莫西沙星和诺氟沙星具有增加跟腱炎和跟腱断裂风险：司帕沙星可导致心脏毒性
喹诺酮类—不良反应 1、胃肠道反应：与剂量有关 2、中枢神经系统反应：可以透过BBB，机制与药物阻断中枢GABA受体有关。轻症表现为失眠、头 疼，重症出现幻觉、抽搐甚至惊厥。常在剂量过大，或有精神病、癫痫史，与茶碱、非甾体抗炎 药合用时产生。 3、皮肤反应和光敏反应：少数患者发生光敏反应，表现为光照部位红肿、瘙痒和灼热感，严重可 出现皮肤糜烂和脱落。光敏反应与喹诺酮类药物结构有关，其中司帕沙星、洛美沙星、氟罗沙星 最易导致光敏反应。 4、软骨损害：软骨组织中的镁离子易与药物形成络合物，沉积于关节软骨，造成局部Mg2+缺乏 致软骨损伤。孕妇和18岁以下禁用。 5、其他：环丙沙星、氧氟沙星、吉米沙星、莫西沙星和诺氟沙星具有增加跟腱炎和跟腱断裂风险； 司帕沙星可导致心脏毒性
喹诺酮类一不良反应U.S.Department ot Health andHuman ServicesAtoZIndexFoilowFDAEnEspandU.S.FOOD & DRUGFDAQSearchFDAADMINISTRATIONCosmeticsTobaccoProductsMedical DevicesRadiation-Emiting ProductsVaccines,Blood&BiologicsAnimal&VeterinaryHomDruasDrugsHome>DrugsDrugSafetyandAvailabilltyFDADrugSafetyCommunication:FDAupdatesDrug Safety and AvailabiltywarningsfororalandinjectablefluoroguinoloneDrug Alerts and StatementsantibioticsduetodisablingsideeffectsMedication GuidesfSHAREInLNKEOINEADrug Safety CommunicationsDrug ShortagesThis information isanupdateto theFDADrug SafetyCommunication:FDAadvisesrestricting fluoroquinoloneantibioticusefor certain uncomplicatedinfections; wams about disabling side effects thatcan occurtogetherPostmarket Drug SatetyissuedonMay.12.2016tnformationforPatientsandProvide
喹诺酮类—不良反应
喹诺酮类一不良反应SafetyAnnouncement[7-26-2016] The U.S.Food andDrugAdministration (FDA)approved changes to thelabelsoffluoroquinoloneantibacterial drugsfor systemic use (i.e.,takenbymouthorby injection).Thesemedicinesareassociatedwithdisablingandpotentiallypermanentsideeffectsofthetendons,muscles,joints,nervesand central nervous systemthat can occurtogetherin the same patient. As a result, werevised the BoxedWarning.FDA's strongestwaning,to address theseserious safety issues.Wealsoaddeda new warningandupdated otherparts of the drug label, including the patient Medication Guide.[05-10-2017]Aspartofourongoingreviewoffluoroquinoloneantibiotics,FDAis informingthepublicthatpatientcasesidentified bytheFDA and findings from published studies currentlydo not supportreports thatthese medicines mayresult indetachment of theretina in theeyes,orbulges ortears in theaorta bloodvesselcalledaorticaneurysmandaorticdissection.Wewillcontinuetoassesssafetyissueswithfluoroquinolonesand will updatethepublic ifadditionalactionsareneeded
喹诺酮类—不良反应